vinpocetine has been researched along with Schizophrenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, C; Fu, B; Liu, N; Xu, Y; Zheng, Y | 1 |
| Abdel-Sattar, SA; Ahmed, HI; Zaky, HS | 1 |
2 other study(ies) available for vinpocetine and Schizophrenia
| Article | Year |
|---|---|
Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disks Large Homolog 4 Protein; Ketamine; Male; Neuroprotective Agents; Rats; Schizophrenia; Synapses; Vinca Alkaloids | 2019 |
Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; beta Catenin; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3 beta; Hippocampus; Ketamine; Male; Malondialdehyde; Oxidative Stress; Rats, Sprague-Dawley; Schizophrenia; Signal Transduction; Vinca Alkaloids | 2018 |